Accustem Sciences Inc (ACUT)

Data delayed 15 minutes

Trading terms

Trading hours (UTC)
lunedì: 11:00 - 00:00
martedì - venerdì: 00:00 - 00:30, 11:00 - 00:00
sabato: 00:00 - 00:30

About

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.

https://www.aclaristx.com/
х
Avviso di rischio: Trading sui mercati finanziari comporta dei rischi. Il valore degli investimenti può sia aumentare che diminuire e gli investitori possono perdere tutto il loro capitale investito. Nel caso di un prodotto con effetto leva, la perdita può essere superiore al capitale iniziale investito. Informazioni dettagliate sui rischi associati al trading sui mercati finanziari si trovano nella informativa completa sui rischi.